Latest news with #SpherixGlobalInsights
Yahoo
07-08-2025
- Health
- Yahoo
Rheumatologists Eagerly Anticipate Pipeline Advancements in Idiopathic Inflammatory Myopathies to Address Deep Unmet Need, According to Spherix Global Insights
Inclusion body myositis and ASyS identified as most underserved IIM subtypes amid widespread calls for faster, safer, steroid-sparing therapies. EXTON, PA, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Despite recent increased use of intravenous immunoglobulin (IVIg) and biologics, the majority of patients with idiopathic inflammatory myopathies (IIM)—including classic dermatomyositis (DM), polymyositis (PM), and clinically amyopathic dermatomyositis (CADM)—remain inadequately managed, according to new research from Spherix Global Insights. The latest Market Dynamix™: IIM (US) study, based on research conducted with 104 rheumatologists and six in-depth interviews, reveals persistent challenges in managing this complex and heterogenous group of rare autoimmune conditions, particularly for patients with DM and PM, which together make up the majority of IIM cases under rheumatologist care. Glucocorticoids remain the dominant first-line treatment across IIM subtypes, but their long-term use is widely viewed as problematic. Fewer than half of DM and PM patients—and just over half of those with CADM—are considered well-controlled on current regimens. Nearly all rheumatologists report turning to combination therapy to improve outcomes, with methotrexate most commonly added to glucocorticoids. Yet, few physicians express satisfaction with available options for DM and PM. Steroid minimization is a central, yet often elusive, goal—hampered by limited access to effective and targeted alternatives. CADM adds further complexity due to its dermatologic dominance and inconsistent response to immunosuppressants. Rare forms of IIM, including anti-synthetase syndrome (ASyS), necrotizing myopathy (NM), and inclusion body myositis (IBM), present even greater clinical complexity. These subtypes are often under-recognized, slow to diagnose, and highly refractory to existing treatments. IBM is rated the most challenging IIM subtype to manage, followed closely by ASyS and NM. Rheumatologists report that these conditions demand earlier, more aggressive intervention, often involving IVIg, rituximab, and combination DMARD strategies—especially when interstitial lung disease (ILD) or severe muscle involvement is present. Still, barriers related to diagnosis, insurance coverage, and the absence of disease-modifying agents are frequently reported. '[The] ability to treat patients with medication that specifically treats the disease overall rather than manifestations of the disease [is needed]—especially in those with pulmonary or cardiac manifestations,' one physician emphasized. 'Making the diagnosis is also challenging initially.' Looking ahead, rheumatologists are placing high hopes on emerging therapies in development, particularly those that could offer safe, rapid, and steroid-sparing disease control. AstraZeneca's Saphnelo (anifrolumab) leads in preference due to familiarity in lupus, a targeted mechanism, and strong efficacy data. Priovant Therapeutics' brepocitinib, a dual TYK2/JAK1 inhibitor delivered orally, is also highly favored for its potential convenience and broad anti-inflammatory reach. Other pipeline candidates generating excitement include argenx's efgartigimod, noted for its similarity to IVIg and potential to induce long-term remission; Pfizer's dazukibart, an interferon-targeting mAb with monthly IV dosing; and CD19-directed CAR T-cell therapies such as KYV-101(Kyverna Therapeutics), viewed as the most promising long-term innovation due to curative potential. Across all IIM subtypes, the demand for innovation is unmistakable. Rheumatologists emphasize the need for therapies with faster onset, broader disease targeting (muscle, skin, lung), and greater patient convenience, such as once-daily oral administration. With nearly half of IIM patients estimated to be candidates for advanced systemic therapies, the market is primed for disruption—particularly by agents that offer strong safety, durable efficacy, and a reduced reliance on corticosteroids. Market Dynamix™ is an independent, data-driven service focused on understanding the evolving dynamics of specialty markets poised for disruption. Leveraging quantitative and qualitative research, the service evaluates current treatment approaches, unmet needs, and likely impact of pipeline agents over a three-to-five-year horizon. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. CONTACT: Andy Stankus, Rheumatology Franchise Head Spherix Global Insights 4848794284 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
06-08-2025
- Health
- Yahoo
Johnson & Johnson Innovative Medicine's Tremfya Gains Momentum in Crohn's Disease, Outpacing Eli Lilly's Omvoh and Challenging AbbVie's Skyrizi
Strong efficacy and safety perceptions, as well as favorable administration fuel utilization of the IL-23 class in Crohn's disease, according to Spherix Global Insights. EXTON, PA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The Crohn's disease (CD) treatment landscape is undergoing a radical transformation as newer mechanisms of action (MOAs), particularly IL-23 inhibitors and JAK inhibitors, continue displace long-standing therapies like TNF inhibitors. With the recent FDA approvals of Tremfya (guselkumab) and Omvoh (mirikizumab), joining Skyrizi (risankizumab) earlier this year, all three IL-23 inhibitors are now commercially available for CD. Although each has been on the market for several months, new data from Spherix Global Insights indicate Tremfya is quickly emerging as a standout among US gastroenterologists. According to the latest results from Spherix's RealTime Dynamix™: Crohn's Disease (US) service, IL-23 brand share reported by gastroenterologists (n=104) more than doubled year-over-year, largely at the expense of TNF inhibitors. This momentum has also begun to temper the growth of Rinvoq (upadacitinib). Furthermore, more than half of respondents now identify the IL-23 class as the most effective MOA for CD, a perception that has intensified significantly over the past year. In a recent interview, Stephen B. Hanauer, MD, medical director of the Digestive Health Center at Northwestern Medicine and the Clifford Joseph Barborka Professor of Medicine at Northwestern University Feinberg School of Medicine, shared his perspective on the IL-23 class's rapid rise: 'The advantages of the IL-23s are really three-fold. They are highly effective. Like any other agent, they're most effective in biologic naive patients. They do have efficacy in bio-exposed patients, but slightly diminished absolute response rates. They are very safe agents and not associated with severe infections or cancer. They are also easy to administer on an every month or every other month basis.' While IL-23s have primarily been used as second-line or later therapies, physicians increasingly express a desire to move them earlier in the treatment algorithm. In fact, nearly half of respondents would prefer to use an IL-23 first-line over alternative MOAs. As Dr. Hanauer noted, 'The field is moving toward earlier treatment and that positions the IL-23s very favorably because of their safety profile and because they are considered safe in pregnancy. I think these accumulating recognitions are moving the position of the IL-23s S to first-line therapy for moderate to severe disease.' Despite payer-imposed restrictions, particularly for first-line use in biologic naïve patients, physicians anticipate broader adoption of the class as familiarity and formulary positioning improves. Among the IL-23s, Tremfya is quickly emerging as a key contender in the US Crohn's market, despite being the last to gain approval. According to findings from Spherix's Launch Dynamix™: Tremfya in Crohn's Disease (US) service, the product has seen rapid uptake, with three-quarters of surveyed gastroenterologists (n=76) reporting use within three months of launch. Tremfya has already surpassed Omvoh in reported share and is projected to double its footprint over the next six months. Physician satisfaction is strong, driven by favorable efficacy and safety ratings, and nearly one in five Tremfya prescriptions occurring in the first-line advanced setting. A key differentiator fueling Tremfya's adoption is its unique induction flexibility, offering both subcutaneous (SC) and intravenous (IV) options, a feature that is not currently available with the other IL-23s. Gastroenterologists also highlight Tremfya's dual MOA, rapid symptom relief, and versatility across a broad spectrum of patient types, including those with co-existing dermatologic conditions. As one gastroenterologist shared: 'I like Tremfya for patients who have coexisting conditions, like psoriasis. It works across IBD and dermatologic pathways. In general, I believe Tremfya works across all groups. I like it for young people, older people. You don't have to worry about those that have underlying cardiovascular risk factors. It has a great safety profile." Tremfya currently holds the highest manufacturer launch rating among IL-23s in CD, supported by strong field engagement as most gastroenterologists report recent interactions with a Tremfya representative. Overall awareness and familiarity are strong, with three-quarters of physicians indicating high unaided awareness and confidence in their knowledge of the brand. While enthusiasm for Tremfya is evident, some barriers remain. Physicians note that multiple dosing regimens may be confusing for patients who prefer simpler options, and there remains uncertainty around insurance coverage as the product finds its footing. Nevertheless, gastroenterologists overwhelmingly agree that Tremfya fills an unmet need, offering a favorable balance of efficacy and safety compared to more established biologics. As one gastroenterologist summarized: 'Tremfya helps fill an unmet need by offering strong efficacy while matching or surpassing the safety profile of older biologics like Entyvio.' With strong early adoption, a differentiated clinical profile, and growing prescriber confidence, Tremfya is well-positioned to challenge existing players and reshape the competitive dynamics of the Crohn's disease treatment landscape. Spherix Global Insights will continue to track its progress and emerging trends in both the US and European markets through its Launch Dynamix™ and RealTime Dynamix™ services. RealTime Dynamix™ is an independent service providing strategic guidance through quarterly or semiannual reports, which include market trending and a fresh infusion of event-driven and variable content with each wave. The reports provide an unbiased view of the competitive landscape within rapidly evolving specialty markets, fueled by robust HCP primary research and our in-house team of experts. Launch Dynamix™ is an independent service providing monthly benchmarking of newly launched products for the first eighteen months of commercial availability, augmented by a quarterly deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and analysis addressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. CONTACT: Jim Hickey, Gastroenterology Franchise Head Spherix Global Insights 4848794284 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
06-08-2025
- Health
- Yahoo
Beyond Gene Therapy: Pyruvate Kinase Activators (Agios, Novo Nordisk) Offer a New Route to Address Hemoglobin, VOCs, and Transfusion Burden in Sickle Cell Disease
Physician perspectives point to strong interest in metabolic modulation as a novel pathway in sickle cell disease, particularly for patients who cannot currently access gene therapy for clinical or logistical reasons, according to Spherix Global Insights. EXTON, PA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- According to the latest findings from Spherix Global Insights' syndicated Market Dynamix™ service, the US sickle cell disease (SCD) market is approaching a pivotal juncture, with gene therapies and novel oral agents, including pyruvate kinase (PK) activators, garnering heightened enthusiasm among treating hematologists. While the promise of innovation is substantial, real-world barriers in access, adherence, and patient support continue to temper expectations. SCD is marked by chronic hemolytic anemia and recurrent vaso-occlusive crises (VOCs), driven in part by the reduced lifespan and impaired function of red blood cells. By targeting red blood cell energy metabolism, PK activators such as mitapivat (Agios) and etavopivat (Novo Nordisk) aim to enhance ATP production and reduce 2,3-DPG levels, thereby improving red blood cell survival, oxygen affinity, and resilience against sickling. This metabolic modulation, physicians note, offers a fundamentally different – and potentially complementary – pathway to existing disease-modifying agents. Surveyed hematologists see these agents as particularly promising for their ability to address multiple clinical challenges simultaneously: raising hemoglobin, reducing transfusion dependence, and decreasing VOC frequency. On average, physicians report that roughly 40% of their SCD patients could be appropriate candidates for PK activator therapy, with potential utility in both transfusion-dependent and non-transfusion-dependent populations. Oral administration, favorable safety profiles, and the opportunity for earlier intervention further enhance their appeal. Still, while enthusiasm runs high, physicians stress the importance of long-term efficacy and safety data, particularly regarding sustained hemoglobin improvement and meaningful VOC reduction. Many anticipate that, if approved, PK activators will be incorporated into combination approaches or used to bridge patients to curative options such as gene therapy. As the treatment paradigm evolves, hematologists continue to seek therapies that can be integrated into real-world care with minimal burden, offering both efficacy and convenience. The growing interest in PK activation reflects a broader shift toward diversifying mechanisms of action to better address the multifaceted nature of SCD. Market Dynamix™ is an independent, data-driven service focused on understanding the evolving dynamics of specialty markets poised for disruption. Leveraging quantitative and qualitative research, the service evaluates current treatment approaches, unmet needs, and likely impact of pipeline agents over a three-to-five-year horizon. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. CONTACT: Sarah Hendry, Hematology Franchise Head Spherix Global Insights 4848794284 in to access your portfolio
Yahoo
17-07-2025
- Health
- Yahoo
GSK's Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights
Despite new market entrants in the form of Gilead's Livdelzi and Ipsen's Iqirvo, US gastroenterologists report nearly half of PBC patients suffer from moderate to severe pruritus, underscoring an existing unmet need. EXTON, PA, July 17, 2025 (GLOBE NEWSWIRE) -- The treatment landscape for primary biliary cholangitis (PBC) has undergone a marked transformation over the past year, driven by the recent approvals of Gilead's Livdelzi (seladelpar) and Ipsen's Iqirvo (elafibranor). These additions to the therapeutic arsenal represent meaningful progress in disease management. However, new data from Spherix Global Insights' Market Dynamix™: Primary Biliary Cholangitis and Primary Sclerosing Cholangitis 2025 (US) reveal that pruritus—a persistent and often debilitating symptom—continues to pose a significant unmet need for many patients living with PBC. Among the 104 US gastroenterologists surveyed in the study, there was near-universal agreement on the importance of addressing pruritus—one of the most burdensome and distressing symptoms associated with PBC. Respondents estimated that approximately half of their PBC patients suffer from moderate to severe pruritus, a manifestation that significantly impacts quality of life and remains challenging to manage. As one specialist poignantly noted, 'Patients with cholestatic liver disease will go to the world's end to escape from pruritus and the insomnia it causes.' Most gastroenterologists surveyed also acknowledged a substantial unmet need for therapies specifically targeting PBC-associated pruritus. While Livdelzi has demonstrated a significant reduction in itch symptoms after six months of treatment, only about half of respondents reported that their patients on Livdelzi required no additional intervention for pruritus. The need for effective symptom control is even more pronounced among patients receiving Iqirvo, further highlighting the gap in adequate pruritus management and the continued demand for novel therapeutic approaches. In June, GSK announced that the FDA had accepted the New Drug Application (NDA) for its ileal bile acid transporter (IBAT) inhibitor, linerixibat, for the treatment of cholestatic pruritus in patients with PBC. The PDUFA target action date is set for March 24, 2026. Awareness of the IBAT class is already high among gastroenterologists, and most report they are likely to incorporate linerixibat into their treatment armamentarium if approved. As one specialist expressed, 'The results seem promising with a significant symptom reduction among moderate to severe pruritus. However, abdominal pain and diarrhea side effects are somewhat concerning and may limit real-world use.' Another echoed the sentiment, noting, 'It significantly improved symptoms of pruritus along with quality of life, which can be a challenging and quite debilitating symptom to treat.' If approved, linerixibat could represent a meaningful advancement for patients struggling with PBC-related pruritus—a symptom that continues to profoundly impair quality of life and remains inadequately addressed by current therapies. Spherix Global Insights will continue to closely track emerging developments across the PBC treatment landscape and pipeline through its Market Dynamix™: Primary Biliary Cholangitis and Primary Sclerosing Cholangitis service. Market Dynamix™ is an independent service providing analysis of markets anticipated to experience a paradigm shift within the next three to five years. Insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and analysis addressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. CONTACT: Jim Hickey, Gastroenterology Franchise Head Spherix Global Insights 4848794284 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-07-2025
- Health
- Yahoo
Biologic Competition, Payer Pressures, and Gene Therapy Momentum Define a Pivotal Moment in nAMD and DME Management, According to Spherix Global Insights
More than 70% of surveyed U.S. ophthalmologists anticipate a fundamentally transformed approach to managing nAMD and DME within the next five years. Exton, Pennsylvania, July 10, 2025 (GLOBE NEWSWIRE) -- Recently released research from Spherix Global Insights provides a timely look at the increasingly competitive and complex treatment landscape for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). The Q2 wave of the syndicated RealTime Dynamix™ studies—based on responses from more than 100 U.S. ophthalmologists, primarily retina specialists—captures current prescribing dynamics, perceptions of leading therapies, and evolving expectations shaped by emerging treatments and payer influence. Study findings reveal Roche/Genentech's Vabysmo continues to command the lead in the retina market, earning strong marks for efficacy, physician satisfaction, and flexible dosing. Regeneron's Eylea HD is steadily gaining ground as retina specialists sharpen their focus on newer, longer-acting options. At the same time, Eylea 2mg remains the preferred second line product, after Avastin, due to its long-term data, efficacy, and safety profile. Despite high awareness, biosimilars remain on the periphery—particularly in the first-line setting. While many physicians are open to their use in principle, uptake remains modest, constrained in part by clinical conservatism and concerns about interchangeability. However, many ophthalmologists acknowledge that the payer environment could force a shift, especially if step therapy mandates begin to require biosimilar trials before branded biologic access. Payer influence continues to cast a long shadow over treatment decisions, with roughly three-quarters of respondents reporting that coverage restrictions, prior authorization requirements, and cost-sharing concerns regularly impact prescribing choices. Physicians estimate that one in three patients with nAMD or DME are likely receiving less-than-optimal care due to these access-related hurdles. Most practices now rely on dedicated biologic coordinators to manage the administrative load, but even with support staff in place, prior authorizations remain a major friction point. The increasing use of AI-driven auto-denial systems is only exacerbating these delays, introducing new workflow inefficiencies, and stalling the initiation of preferred therapies. Amid this increasingly complicated environment, gene therapies are offering a sense of future promise. Ophthalmologists are optimistic about the long-term potential of assets in development such as 4DMT's 4D-150, AbbVie's ABBV-RGX-314, and Adverum's Ixo-vec. These agents are generating significant anticipation for their ability to reduce treatment burden and deliver transformative durability, potentially redefining the landscape beyond traditional biologics. Indeed, as the in-line competitive field tightens and new options on the horizon expand, over 70% of ophthalmologists expect a fundamentally reshaped treatment landscape within the next five years. The latest Q2 update of the RealTime Dynamix™ series include responses from 112 U.S. ophthalmologists (101 for nAMD; 100 for DME) with high-volume patient caseloads. Data were collected between May 5 and June 11, 2025. As the market continues to shift under the pressure of payer dynamics and pipeline disruption, Spherix will continue to track these developments and deliver actionable insights to keep stakeholders ahead of the curve. RealTime Dynamix™ is an independent service providing strategic guidance through quarterly or semiannual reports, which include market trending and a fresh infusion of event-driven and variable content with each wave. The reports provide an unbiased view of the competitive landscape within rapidly evolving specialty markets, fueled by robust HCP primary research and our in-house team of experts. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and analysis addressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. CONTACT: Bob Shewbrooks, Ophthalmology Franchise Head Spherix Global Insights 4848794284
